Importance
==========

This is the first study that analyzes the interactive effects of 28 clinical and virological features in the intrahost evolution of HIV-1 in pediatric patients during a long HIV-1 exposure time. During the HIV infection, clinical, epidemiological, and virological parameters fluctuate over time, presenting differences across patients. These parameters seemed to be relevant in the course of the infection and HIV-1 evolution. Understanding whether variation in these clinical parameters also affect within-host HIV-1 evolution may also help to design more efficient control strategies. However, more related studies are required for a better understanding of HIV evolution in children and adolescents.

Introduction
============

RNA viruses present high potential for generating large population genetic diversities at the intra and interhost levels ([@evx193-B26]; [@evx193-B22]; [@evx193-B21]; [@evx193-B50]). This provides a high capacity for viral adaptation to new environments, which may represent an enormous evolutionary advantage with far-reaching consequences for key viral traits such as disease progression, infectivity, transmissibility, and response to antiviral treatments ([@evx193-B22]; [@evx193-B49]). Thus, understanding the factors that determine the level of intra and interhost genetic diversity in RNA virus populations is required to understand viral disease dynamics ([@evx193-B22]).

Human immunodeficiency virus type 1 (HIV-1) is an RNA virus presenting high genetic diversity mainly due to the high mutation rates derived from the error-prone nature of its reverse transcriptase ([@evx193-B1]; [@evx193-B29]), to its high recombination rate ([@evx193-B59]; [@evx193-B35]), and to the high replication rates and large population sizes ([@evx193-B39]). Levels of HIV-1 genetic diversity differ between HIV-1 subtypes and recombinants ([@evx193-B1]), and may also be affected by clinical factors. A higher within-host HIV-1 genetic diversity in naïve patients has been associated with lower levels of T lymphocyte CD4 count ([@evx193-B31]; [@evx193-B27]), higher viral load ([@evx193-B30]; [@evx193-B53]), larger virus exposure time ([@evx193-B29]; [@evx193-B46]), and age ([@evx193-B9]). In treated patients, antiretroviral therapy (ART) has been demonstrated to have complex effects on HIV genetic diversity, promoting adaptive evolution and fixation of mutations conferring drug resistance ([@evx193-B28]; [@evx193-B37]) or reducing virus genetic diversity ([@evx193-B18]; [@evx193-B24]). However, during the course of an infection or an epidemic, HIV-1 populations face changes in viral load (VL), CD4 count, and ART experience that occur simultaneously. Thus, further analysis of the role of these clinical factors in determining the genetic diversity of HIV-1 populations and of their interactive effects is required ([@evx193-B26]). However, such studies are scant, mainly focused in adult patients and limited to consider the interaction of a maximum of two clinical factors ([@evx193-B9]).

HIV evolution in children has received much less attention than in adults (Carvajal-Rodriguez etal. 2008), even though HIV-1 genetic diversity does not necessarily evolve in the same way in adult and pediatric patients, as clinical features of HIV-1 infection in children and adults are very different. Children present a faster rate of disease progression, substantially higher viremia at early times postinfection and a slower decline after initial infection compared to adult infections ([@evx193-B34]). The clinical course of HIV infection in children also varies according to the age of infection and transmission route. Most of the pediatric infections occur in perinatally infected children ([@evx193-B13]) whose immature immune system would exert less selection pressure on the virus than in adult patients, at least in the early stages of infection ([@evx193-B11]). Indeed, a large variation in immune responses among pediatric patients has been observed ([@evx193-B6]). Disease progression has been shown to differ between patients infected through mother-to-child transmission as compared to those infected by other routes ([@evx193-B56]). In a previous study, our group demonstrates that the HIV-1 between-host evolutionary dynamics differs between children and adult populations of Madrid, and identified three clinical factors (age, CD4/mm^3^ and antiretroviral experience) as major determinants of HIV-1 population genetic diversity ([@evx193-B36]. Higher HIV-1 subtype B genetic diversity was observed with increasing child age, decreasing CD4/mm^3^ and upon antiretroviral experience ([@evx193-B36]. However, HIV1 evolutionary dynamics are not the same at the between- and within-host levels ([@evx193-B10]. This study analyzes the relative importance of 28 clinical/epidemiological/virological parameters in determining within-host HIV-1 subtype B evolution during longitudinal pediatric HIV-1 infection for a better understanding of HIV evolution in children.

Materials and Methods
=====================

Study Population
----------------

The Madrid cohort of HIV-infected children and adolescents (established in 2003) registered 561 HIV-1 infected children until March 2016. We selected those perinatally infected patients carrying HIV-1 subtype B (HIV-1B) with three or more available partial *pol* sequences derived from samples collected within a spanning time of at least two years. Following these inclusion criteria, a total of 24 children were enrolled in the study ([table 1](#evx193-T1){ref-type="table"}). The project was approved by the Human Subjects Review Committee at University Hospital Ramón y Cajal (Madrid, Spain), and informed consent of the parents or guardians was obtained. Table 1.Main Features and Available HIV-1 Sequences from the Study CohortFeaturesPatientsHIV-1 vertical transmission24HIV-1 subtype B24GenderMale15Female9Origin countrySpain22Guatemala1Peru1Year of infection (birth year)1984--198971990--1999152000--20022Year of HIV-1 diagnosis1984--198911990--1999192000--20044Mean age in years (range)At HIV-1 diagnosis^a§^1.7 (0.1--8.6)At first ART^b^3 (0.1--8.5)At baseline sampled sequence^c^8.8 (0.3--18.8)At last sampled sequence^d^16.8 (5--23.9)Mean number of HIV-1 sequences per patient (range)7 (3--21)Years between the first and the last sequence (range)7.7 (2.2--20.3)[^2]

HIV-1B Sequences
----------------

A total of 162 partial HIV-1B *pol* sequences from 24 patients were included in the study. Sequences (1,102 nt) encompassed the complete protease (PR) gene and the nucleotides comprising the first 335 amino acid residues of the reverse transcriptase (RT). For each patient, sequences were obtained at baseline, at least at one intermediate time point, and in the last clinical visit in a time interval ranging from 2.2 to 20.3 years (mean 7.7). From 3 to 24 (mean 7) partial *pol* sequences per patient were included in the analysis ([table 1](#evx193-T1){ref-type="table"}). Sequenced samples were collected during 20 years (from October 1993 to October 2013). Most sequences were generated and previously used by our group for other analyses ([@evx193-B15]; [@evx193-B16]; [@evx193-B43]; Rojas Sánchez et al. 2016). For this study, only 7 of the 162 sequences (4.3%) were newly obtained from HIV-1 infected plasma samples provided by the Paediatric HIV BioBank integrated in the Spanish AIDS Research Network (RIS) RD12/0017/0035 and RD12/0017/0037 ([@evx193-B19]). Samples were processed following current procedures and frozen immediately after their reception. New HIV-1 sequences were generated as previously reported ([@evx193-B15]). Sequence alignments were constructed using MUSCLE 3.7 ([@evx193-B17]) and adjusted manually according to the amino acid sequences using MEGA 6.0.6 ([@evx193-B55]). The full list of GenBank accession numbers from the 162 partial *pol* sequences, year of isolation of the sequenced samples and associated relevant clinical parameters is available in [supplementary file S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online.

Drug Resistance Analysis
------------------------

Drug resistance mutations (DRM) in pretreated patients were defined following the International AIDS Society---USA (IAS) 2015 list ([@evx193-B58]). We recorded the DRM to three drug families: nucleoside analogues RT inhibitors (NRTI), non-NRTI (NNRTI) and protease inhibitors (PI). Among drug-naïve patients, transmitted drug-resistance mutations (TDR) were defined according to the mutation list for Transmitted Drug Resistances surveillance as recommended by the WHO ([@evx193-B7]). Drug susceptibility was predicted using the Stanford HIVdb algorithm (<http://sierra2.stanford.edu/sierra/servlet/JSierra>), which classifies drug susceptibility in four categories depending on mutation scores: susceptible, low-level, intermediate, and high-level resistance.

Genetic Distances and Selection Pressures
-----------------------------------------

Genetic divergence (*d*) was estimated using the Kimura-2-parameters nucleotide substitution model as implemented in MEGA 6.0.6 ([@evx193-B55]), which was the best-fitted nucleotide substitution model as determined by jModelTest 2.1.8 ([@evx193-B14]). Standard errors (SE) of each measure were based on 1,000 bootstrap replicates for permutation tests. Selection pressures were measured as the ratio between the mean number of nonsynonymous (*d*~N~) and synonymous (*d*~S~) nucleotide substitutions per site (*d*~N~/*d*~S~) calculated by the Pamilo--Bianchi--Li method as implemented in MEGA 6.0.6. Individual values of *d*~N~ and *d*~S~ were also obtained. The *d*~N~/*d*~S~ ratio was also estimated at individual codons in the partial *pol* sequence, using different methods implemented in the HYPHY program (SLAC, Single Likelihood Ancestor Counting; FEL, Fixed Effects Likelihood; IFEL, Internal Fixed Effects Likelihood; REL, Random Effects Likelihood; FUBAR, Fast Unbiased Bayesian Approximation) ([@evx193-B25]) to determine whether each codon was under negative (*d*~N~/*d*~S~ \< 1), neutral (*d*~N~/*d*~S~ = 1), or positive (*d*~N~/*d*~S~ \> 1) selection. These analyses were performed after confirmation of the absence of recombinant sequences in our data set by using four different methods available in the RDP4 package: RDP, GENECONV, Bootscan, and Chimaera, and employing the default parameters ([@evx193-B32]). [Supplementary file S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online includes the observed values for *d*, *d*~N~, *d*~S~, and DRM associated with each viral sequence.

Data on Clinical Factors
------------------------

We analyzed the influence of 28 clinical/epidemiological/virological factors on HIV-1 subtype B evolution in children. They included five virological parameters (DRM, DRM to NRTI, DRM to NNRTI, DRM to IP, and VL), five clinical parameters (CD4 and CD8 lymphocytes T counts or cells/mm^3^ and percent, CD4/CD8 ratio) and 18 epidemiological parameters (children's origin, year of infection (birth year), year of HIV-1 diagnosis, age at HIV-1 diagnosis, coinfection with HBV or HBC, year of sampling sequence, patient's age at HIV-1B sequencing, antiretroviral treatment (ART) exposure (naïve or treated), year of first ART, age at first ART, number of previous ART regimen switches, number of antiretroviral drugs used and drug family experience for NRTI, NNRTI, PI, fusion inhibitor, and integrase inhibitor per patient).

Machine Learning Classification Methods
---------------------------------------

We applied supervised classification methods to analyze the relative importance of clinical factors in HIV-1B evolution. We constructed multivariate models using HIV-1B *d*, *d*~N~, *d*~S~, and frequency of DRM as the variables to be predicted, and the previous 28 clinical parameters considered were used as predictors. To build the models, we categorized some of the continuous variables in order to avoid imbalance in the number of instances of each variable. HIV-1B evolutionary parameters were discretized into three categories, according to the three tertiles of the distribution formed by the values of each variable. Thus, HIV-1B evolutionary variables were classified as follows: *d* (\<0.011, 0.011--0.022, \>0.022,); *d*~N~ (\<0.007, 0.007--0.019, \>0.019,); and *d*~S~ (\< 0.002, 0.002--0.075, \>0.075). Data related to DRM were discretized into two categories (presence or absence), either considering the different classes of DRM separately (NRTI, NNRTI, and PI) and all classes as a whole. CD4 and CD8 (count and percent), VL, age at sequencing and age at diagnosis were also discretized following the CDC recommendations ([@evx193-B12]). Prior to model selection analyses, we perform Variance Inflation Factor (VIF) analyses to test for predictor collinearity. Given that VIF was smaller than 2 in all predictors, we did not include any variance--covariance matrix or reduced-rank analyses in machine learning methods.

Machine learning methods in Weka (<http://www.cs.waikato.ac.nz/ml/weka/>) were used to analyze the data. To remove irrelevant variables that could introduce a bias in the predictive models and to evaluate the predictive power of each subset of predictor variables, the Feature Subset Selection (FSS) tool was implemented in the analysis using three different techniques: two univariate methods (1), one multivariate methods (2), and (3) Wrapper method: 1) two univariate algorithms analyze (InfoGainAttributeEval and GainRatioAttributeEval) that explored the importance of each variable separately in the data set; 2) The multivariate algorithm Correlation Feature Selection (CFS) which predicts the value of each individual variable based on the best subset of features using an induction algorithm as a part of the evaluation function; 3) Wrapper methods which uses a search algorithm for predicting the relative usefulness of subsets of variables. To evaluate the contribution of each predictor using Wrapper method, we analyzed the strength of 6 algorithms (classifiers) in order to find the best predictive model: classification tree (J48 tree), Nearest-neighbor (IB-1 and IB-*K*, where *K* = 3), logistic regression and Bayes algorithm (Naive Bayes and tree-augmented Naive Bayesian Network or TAN) testing the whole data set. To evaluate each algorithm or classifier, a set of measures (confusion matrix, true positive \[TP\] rate, true negative \[TN\] rate, precision, accuracy, recall, f-measure, and area under the ROC curve \[AUC\]) were obtained. For each algorithm, HIV-1B evolutionary parameters were considered as the variables to be predicted, and clinical, epidemiological and virological parameters as the predictor variables. We chose the two best algorithms or classifiers for our data set to evaluate the relative importance of each clinical factor. The clinical factors selected with univariate (InfoGainAttributeEval and GainRatioAttributeEval), multivariate and the best Wrapper algorithms providing the highest values of correctly classified instances and the highest area under the ROC curve (AUC) (were considered the most important variables affecting HIV evolution in the pediatric cohort under study. The ROC curve is a graphical representation of sensitivity versus specificity for a binary classifier system. With a higher area (\>0.75), separation of data should be better. Importantly, this representation is independent of the existence of unbalanced sampling).

Results
=======

Clinical, Epidemiological, and Virological Features of the Study Population
---------------------------------------------------------------------------

A total of 24 patients from the Madrid Cohort of HIV-1 infected children and adolescents were enrolled in the study. Their baseline clinical and epidemiological features are shown in [table 1](#evx193-T1){ref-type="table"}. Most were Spanish (91.7%), male (62.5%), diagnosed before 2000 (83.3%), with a mean age of 3 years at first ART experience and under follow up in pediatric units ([table 1](#evx193-T1){ref-type="table"}). The mean age for collection of the first sequenced viral sample (baseline sequence) was 8.8 years (range 0.3 to 18.8 years) and for the last sampled sequence 16.8 years (range 5--23.9 years). Clinical and virological features of the 24 patients were available in the first clinical report (at collection time of the first sequenced viral sample) and in the last ([table 2](#evx193-T2){ref-type="table"}). In the monitored time interval, we observed an increase in the rate of patients with undetectable VL (≤50 copies/ml) from 8.3% to 17.4%; *χ^2^* = 3.73; *P* = 0.052. The number of patients with low CD4 counts (\<500 CD4 cells/mm^3^) also increased from 33.3% to 60.7% (*χ^2^* = 4.52; *P* = 0.033) ([table 2](#evx193-T2){ref-type="table"}). Table 2.Clinical Features of the 24 Patients Included in This StudyFeaturesNumber of PatientsAt First Sampling TimeAt Last Clinical ReportClinical follow-upPediatric Unit2411Adult Unit09Lost to follow-up01Exitus01Unknown02ART statusNaive20Treated2224Regimen switches, mean (range)3.4 (0--12)5.9 (2--12)1--2913--610147--1226Unknown33Previous ARV drugs, mean (range)5.9 (0--18)9.7 (5--18)\<3303--61247--13515\>1314Unknown31Number of DRMTotal126147To NRTI7179To NNRTI2134To PI (major)3434Viral load (HIV-1 RNA-copies/ml)≤5024\>50--50022\>500--1,00022\>1,000--10,00078\>10,000--100,00096\>100,00021Unknown01CD4+ T rate\<25%121625--50%107\>50%00Unknown21CD4+ T cells/mm^3^\<350310350--50044501--1,0001181,001--1,50011\>1,50020Unknown31CD8+ T cells/mm^3^\<35011350--50000501--1,000351, 001--1,50075\>1,50056Unknown87CD4/CD8 mean ratio (range)0.8 (0.1--3)^a^0.4 (0.06--0.9)^b^[^3]

We also analyzed the change of viremia and lymphocyte rate over the course of the infection. We calculated the mean values from CD4 and CD8 rates, CD4/CD8 ratio, and VL along the monitored HIV-1B exposure time. We observed an increase in the CD8 rate over time (*r* = 0.93; *P* = 0.001) ([fig. 1*A*](#evx193-F1){ref-type="fig"}) from 10% in newborns to 65% at the largest HIV-1 exposure time (age of 18 years). We also noticed a nonsignificant decrease in the CD4 rate (*r* = −0.44; *P* = 0.072) ([fig. 1*B*](#evx193-F1){ref-type="fig"}). The CD4/CD8 ratio reached a maximum at early times, and rapidly decreased afterwards, stabilizing its value after 5 years of HIV-1 exposure time. Indeed, we detected a significant logarithmic association between the CD4/CD8 ratio and exposure time (*r* = −0.77; *P* = 0.006) ([fig. 1*C*](#evx193-F1){ref-type="fig"} and [table 2](#evx193-T2){ref-type="table"}). Finally, VL decreased over time (*r* = −0.75; *P *= 0.002) ([fig. 1*C*](#evx193-F1){ref-type="fig"}).

![---Correlations between patient HIV-1B exposure time and T-CD4+ and T-CD8+ rates (*A*), CD4/CD8 ratio (*B*), viral load or VL (*C*) and evolutionary parameters, namely HIV-1B genetic diversity (*D*), mean number of nonsynonymous (*d~N~*) and synonymous (*d~S~*) nucleotide substitutions (*D*). For each correlation the *R*^2^ and the *P* values are shown. Dashed line in panel C refers to undetectable viral load \< 2.7 log (\<500 HIV-1-RNA copies per milliliter of plasma). *P* values: 0.038 (*d*), 0.058 (*d~N~*), 0.450 (*d~S~*), 0.001 (%CD8), 0.006 (CD4/CD8), and 0.002 (VL).](evx193f1){#evx193-F1}

As expected, the 24 patients showed high drug experience and several regimen switches ([table 2](#evx193-T2){ref-type="table"}), and most analyzed viral sequences presented DRMs ([supplementary fig. S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), which did not significantly change in number over time (126/1,128 vs. 147/1,128 *χ^2^*= 1.84, *P = *0.175) ([table 2](#evx193-T2){ref-type="table"}). The most common DRMs at the last available sequence (last report) were: NRTI mutations T215YF (45.8%), D67N (41.6%), K219QR and L210W (each 37.5%), and M184V (33.3%) at RT; NNRTI mutations Y181C (33.3%), K103NR (29.2%), and G190A (25%) at RT; and PI mutations V82ATS (33.3%), M46I (29.2%), I54V (25%) and L90M (25%) at PR ([supplementary fig. S1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Considering each antiretroviral family individually, we observed a similar rate over time of patients carrying DRMs to NRTI (57.3% vs. 53.7%; *χ^2^* = 0.14; *P* = 0.724) and to PI (27.4% vs. 23.1%; *χ^2^*= 0.49; *P* = 0.476) but a significant increase of DRM to NNRTI (12.3% vs. 23.1%; *χ^2^*=3.95; *P* = 0.044). Despite the presence of DRMs in every viral sequence according to the Stanford algorithm, viruses presented preserved susceptibility to some new antiretrovirals (ARVs) such as darunavir (DRV/r) in six children, tipranavir (TPV/r) in four, and etravirine (ETR) and rilpivirine (RPV) in five patients ([fig. 2](#evx193-F2){ref-type="fig"}). During the spanning time between baseline and last analyzed sequence (7.7 years on average, [table 1](#evx193-T1){ref-type="table"}), DRMs to at least one ARV family reverted to wild type (wt) residue in 8 of the 24 children. DRMs to PI, NNRTI, and NRTI reverted to wt in 5, 4, and 2 children, respectively ([supplementary table S2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). One of the two children with available viral sequence before ARV experience was firstly infected with a resistant virus to PI and NRTI, carrying changes V82A at the PR and L210W and T215S at the RT ([supplementary table S2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

![---Predicted susceptibility according to the Stanford HIVdb Interpretation Algorithm among those virus carrying DRM to PI (*n* = 15), to NRTI (*n* = 19) or to NNRTI (*n* = 14) in the first available partial pol sequence (*A*) and to PI (*n* = 10), to NRTI (*n* = 18) or to NNRTI (*n* = 16) in last sequence (*B*) collected after a mean spanning time of 7.7 years (range 2.2--20.3 years). DRM, drug resistance mutations; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-NRTI; r, ritonavir used for boosting; ATV/r, boosted-atazanavir; DRV/r, boosted-darunavir; FPV/r, boosted-fosamprenavir; IDV/r, boosted-indinavir; LPV/r, boosted-lopinavir; NFV, nelfinavir; SQV/r, boosted-saquinavir; TPV/r, boosted-tipranavir; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; d4T, estavudine; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine. The approval year for each drug in Spain was: 1988 (AZT), 1993 (ddI), 1996 (d4T, 3TC, IDV/r, SQV/r), 1998 (NVP, NFV), 1999 (ABC, EFV), 2001 (LPV/r), 2002 (TDF), 2003 (FTC), 2004 (ATV/r, FPV/r), 2005 (TPV/r), 2007 (DRV/r), and 2008 (ETR); data available at Agencia Española de Medicamentos y Productos Sanitarios (<https://www.aemps.gob.es/>).](evx193f2){#evx193-F2}

Within-Host HIV-1B Genetic Diversity and Selection Pressures
------------------------------------------------------------

Average within-host HIV-1B genetic diversity in the analyzed virus population was of 0.004 ± 0.001, but varied up to one order of magnitude between patients (*d*: from 0.003 ± 0.000 to 0.040 ± 0.001) ([table 3](#evx193-T3){ref-type="table"}). In addition, averaged nonsynonymous and synonymous diversities were of 0.003 ± 0.001 and 0.008 ± 0.003, respectively, with both evolutionary parameters greatly varying among patients (*d*~N~: from 0.001 ± 0.000 to 0.032 ± 0.001; *d*~S~: from 0.002 ± 0.001 to 0.058 ± 0.003) ([table 3](#evx193-T3){ref-type="table"}). The analyzed *pol* fragment was on average under negative selection (*d*~N~/*d*~S~: 0.565 ± 0.386). Indeed, HIV-*pol* was under negative selection (*d*~N~/*d*~S~ significantly smaller than 1) in 14 (58.4%) patients, under positive selection (*d*~N~/*d*~S~ values \> 1) in 9 children (37.5%) and under neutral evolution in the remaining child (4.1%). Table 3.Evolutionary Parameters of the Partial *pol* Sequences Obtained from 24 HIV-1B Population Under StudyCodeHIV Exposure Time (years)No Sequences*d^1^d*~N~^2^*d*~S~^3^*d*~N~/*d*~S~^4^MeanSEMeanSEMeanSEMeanSEP182.330.0040.0010.0030.0010.0080.0030.5650.386P11660.0280.0080.0180.0040.0500.0191.7360.508P146.850.0150.0070.0080.0040.0240.0120.2220.111P247.330.0280.0090.0200.0050.0400.0130.6280.092P19200.0170.0010.0200.0020.0060.0011.9190.262P1710.730.0200.0040.0100.0020.0440.0090.2540.022P1610.750.0060.0010.0040.0010.0100.0030.6700.268P511.760.0060.0030.0070.0040.0020.0012.4441.222P412.5110.0220.0040.0240.0040.0130.0041.6650.416P212.8200.0400.0010.0300.0010.0580.0030.7900.011P101340.0090.0020.0070.0020.0180.0030.3500.117P1914.330.0180.0060.0150.0060.0200.0040.6570.205P2214.340.0040.0010.0020.0000.0070.0010.2870.038P314.6180.0150.0050.0080.0020.0300.0090.1990.035P2014.730.0080.0010.0060.0030.0090.0031.2150.764P2114.740.0120.0050.0140.0050.0050.0021.8500.513P915.650.0290.0010.0260.0010.0310.0021.0040.058P2315.730.0070.0020.0040.0010.0110.0040.2350.074P1215.990.0030.0000.0010.0000.0060.0010.1520.054P131650.0370.0110.0270.0060.0530.0202.2200.818P121650.0260.0010.0320.0010.0080.0021.7240.145P818.650.0070.0000.0060.0000.0070.0000.5110.043P1519.850.0200.0020.0140.0010.0350.0050.3590.039P725.670.0080.0020.0090.0020.0070.0011.1850.168Total/Average121620.0040.0010.0030.0010.0080.0030.5650.386[^4]

Average evolutionary parameters varied over the course of the infection. Genetic diversity (substitutions per site) increased between the baseline and the last report (from 0.052 ± 0.006 to 0.090 ± 0.014; *r *= 0.54; *P *= 0.038) ([fig. 1*D*](#evx193-F1){ref-type="fig"}). This was due to the accumulation of nonsynonymous mutations (from 0.033 ± 0.005 to 0.086 ± 0.004; *r *= 0.50; *P *= 0.058), whereas synonymous mutations remained relatively constant over time (from 0.088 ± 0.009 to 0.123 ± 0.011; *r *= 0.21; *P *= 0.450). When comparing the baseline versus the last collected viral sequences, we also observed a significant increase in the number of sites under neutral evolution (115/334 vs. 293/334 *χ^2^*= 10.32, *P = *0.002).

Relative Contribution of Clinical Factors to the Evolution of the Pediatric HIV-1B Population
---------------------------------------------------------------------------------------------

The relative contribution of each analyzed clinical factor on HIV-1B evolution was obtained after analyzing how each considered clinical factor predicted HIV-1B evolution using six classifiers (J48 tree, IB-1, IB-3, logistic regression, Naive Bayes, and TAN). We observed different accuracy among these classifiers; IB1, IB3 and J48 were the best classifiers. They showed the highest percentage of correctly classified instances (83.1%, 81.4%, and 76.5%, respectively), good precision and high F-Measures (0.83, 0.81, and 0.76) and high AUC (≥0.8) ([supplementary file S4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). To identify the best predictors of HIV-1B evolution as estimated by IB1, IB3, and J48, we used three different techniques: two univariate algorithms (InfoGainAttributeEval and GainRatioAttributeEval), one multivariate algorithm (CFS) and Wrapper (Wrapper/IB1, Wrapper/IB2, and Wrapper/J48).

[Table 4](#evx193-T4){ref-type="table"} shows the best predictors of HIV-1B evolutionary parameter and DRM presence, which were more frequently obtained by univariate, multivariate, and wrapped algorithms. Associated with HIV-1B *d*, we found the variable age of HIV-1 diagnosis (values of: 0.105 by GainRatioAttributeEval, 80% by CFS, 100% by Wrapper/IB3 and Wrapper/J48, 70% by Wrapper/IB1). For HIV-1B *d~N~*, the best predictors was age at first ART (values of 0.226 by GainRatioAttributeEval, 60% by CFS and 100% by Wrapper/IB3 and Wrapper/J48); and for HIV1-B *d~S~*, an association with variable year of HIV-1 diagnosis was detected (values of 0.211 by GainRatioAttributeEval, 50% by CFS and 100% by Wrapper/IB1, 90% by Wrapper/IB3, 70% by Wrapper/J48). These three epidemiological variables are interrelated, as most of the children involved in this study had received ART at HIV-1B diagnosis time. Table 4.Consensus Best-Predictor Variables for Each Evolutionary Parameter and for Drug Resistance Mutations Presence in the Study CohortEvolutionary parametersARV resistance*dd*~N~*d*~S~Major DRMs to PIDRMs to NRTIDRMs to NNRTIDRMs presenceConsensusbest-predictor variablesAge of HIV-1 diagnosisAge at first ARTYear of infectionYear of infectionYear of infectionNNRTI experienceSampling yearYear of infectionNNRTI experienceYear of HIV-1 diagnosisPatient's originCoinfection with HCV or HBVNo. of ARVsNo. of previous ART regimen switchesNo. of previous ART regimen switchesNo. of ARVsCoinfection with HCV or HBVCoinfection with HCV or HBVNo. of ARVsCD4/CD8 ratioCD4 cel/mm3switchesYear at first ARTYear of HIV-1 diagnosisYear of first ARTAge at first ART%CD8%CD4Year of infectionYear of HIV-1 diagnosisCD8 cell counts/mm^3^Age at first ARTNo. of previous ART regimen switches%CD4CD8 cell counts/mm^3^Year of HIV-1 diagnosisNNRTI experienceCD4/CD8 ratioPI experienceYear of HIV-1 diagnosisYear of first ART%CD8CD8 cell/m^3^No. of previous ART regimen switchesNo. of ARVsSampling yearAge at sequencingIint experienceSampling yearIP experienceCD4 cell/mm^3^Age at first ART%CD8[^5]

In addition, our analyses indicated that year of infection (birth year) and year of sequencing were relevant for the development of DRMs at large (0.116 by GainRatioAttributeEval, 100% by CFS, for birth year; 0.116 by GainRatioAttributeEval, 100% by CFS and 60% by Wrapper/J48, for year of sequencing), DRMs to PI (0.168 by GainRatioAttributeEval, 100% by CFS and 100% by Wrapper/J48, 90% by Wrapper/IB1 and Wrapper/IB3 and, for birth year; 60% by CFS for year of sequencing), and DRMs to NRTI (0.149 by GainRatioAttributeEval, 60% by CFS, 90% by Wrapper/IB1, Wrapper/IB3, and Wrapper J48, for birth year; 90% by CFS and 60% by Wrapper/IB1 for year of sequencing) ([supplementary file S4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Other clinical factors had lesser relevance in HIV-1B evolution (both as genetic diversity and DRM fixation) such as year of infection, experience to different ART, number of previous regimen switches, CD8T+ Cell/mm4 and %CD4 and CD4/CD8 ratio ([table 4](#evx193-T4){ref-type="table"} and [supplementary file S4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

To test the robustness of our estimates, we performed FSS analyses, which also indicated that IB1, IB3, and J48 were the supervised classification paradigms that reported the highest values of precision, and identified the same variables as the best predictors of HIV-1B evolution after Infogain, Gain Ratio, and CFS analyses ([table 5](#evx193-T5){ref-type="table"}). Table 5.Percentage of Correctly Classified Instances by Each Model Using Wrapper, Gain Ratio, and CFS Data Sets in Our Study CohortModelData setParameter*dd*~N~*d~S~*Major DRM to PIDRM to NRTIDRM to NNRTIDRM presenceJ48WrapperCorrectly classified instances47.4%79.3%76.4%91.5%86.7%80.6%93%Gain ratio86.1%66.8%72.8%77.9%80.6%79.6%89.3%CFS68%68.9%63.6%81.2%85.1%80.1%90.6%IB1Wrapper37.1%69.4%72.8%87.7%82.6%80.1%86.8%Gain ratio78.4%73.6%75.9%92.5%83.7%86.6%92.5%CFS76.3%68.4%67.7%85.5%82.4%83.3%93.1%IB3Wrapper47%68%67%88.7%85%79%91.8%Gain ratio74.2%70.9%75.4%85.9%83.2%87.1%93.1%CFS73.7%68.4%64.1%73.7%89.2%85.5%94.9%[^6]

Discussion
==========

This is the first study that analyzes the interactive effects of more than two clinical and virological features in the intrahost evolution of HIV-1 in pediatric patients during a long HIV-1 exposure time. During the HIV infection, clinical, epidemiological, and virological (VL, DRM) parameters fluctuate over time, presenting differences across patients, as we observed in our population study. These parameters may be relevant for the course of the infection and for HIV-1 evolution. Previous results from our group indicate that some of these parameters (children age, decreasing CD4/mm^3^, and upon antiretroviral experience) are key determinants of HIV-1 between-host evolution ([@evx193-B36]). Understanding whether variation in these clinical parameters also affect within-host HIV-1 evolution may help to design more efficient control strategies ([@evx193-B40]). Our study showed that the best-predictor variables for HIV-1B evolutionary parameters were the age of HIV-1 diagnosis for *d*, the age at first ART for *d~N~* and the year of HIV-1 diagnosis for *d~S~*. The year of infection (birth year) and the year of sampling seemed to be relevant for fixation of both DRM at large and, considering drug families, to PI.

In this study, we applied machine learning algorithms whose main benefit is the ability to analyze big data sets and construct accurate predictive models, accommodating all types of predictors and response variables ([@evx193-B38]). Importantly, and at odds with most classical methods, these algorithms allow incorporating a stochastic component to model construction. We used six supervised classification methods to predict three HIV-1B evolutionary parameters (*d*, *d*~N~, and *d*~S~) and the fixation of DRM. Supervised classification techniques are algorithms with high predictive power and are designed to optimize the statistical classification procedures ([@evx193-B54]). Among these six methods, IB1, IB3, and J48 generated the best predictor models. Although not all these methods allow building an explicit predictive model, our results suggest that these showed advantages over other methods since they required less preprocessing, had a better performance in the presence of interacting features, generally required less training data to learn good settings, and were more cost-efficient than others. Although multivariate analyses have been extensively used to study others HIV-infected cohorts and clinical studies ([@evx193-B42]; [@evx193-B5]; [@evx193-B20]; [@evx193-B8]; [@evx193-B47]), this is the first time that machine learning techniques have been applied to understand the importance of clinical parameters in determining within-host HIV-1 subtype B.

Most HIV-infected children under study were born in the 80's--90's (75%), had detectable VL (\>50 c/ml) at last sequence (83.3%) and had monotherapy and/or dual therapy experience (34.8%), leading to treatment failure and reducing ART efficacy due to the incomplete virus suppression after DRM selection ([@evx193-B28]; [@evx193-B2]; Rojas Sánchez and Holguín 2014). In fact, treatment failure in children during ART is frequent, leading to immunological damage ([@evx193-B23]) and the emergence of DRMs is a major obstacle for effective treatment (Rojas Sánchez and Holguín 2014). Clinicians face problems of managing heavily pretreated perinatally infected patients with many resistance mutations, not completely adherent to the treatments or with previous suboptimal regimens, such as in those children born in the mono or biotherapy era or in areas with limited ARV availability. In our study, all 24 patients (except one child) carried viruses with DRMs at first and last available sequence, although they maintained susceptibility to some antiretroviral drugs licensed or under evaluation to control HIV pediatric infection (<https://www.aemps.gob.es/>). The high resistance rate to most ARVs across resistant viruses reflects the change of treatment choices by clinicians during the last decades depending on the approval time of ARV for pediatric use in Spain ([fig. 2](#evx193-F2){ref-type="fig"}).

The effect of ART on plasma HIV-1 diversity has been studied in adults ([@evx193-B28]; [@evx193-B37]; [@evx193-B18]; [@evx193-B24]). We previously observed an increase of the mean between-host virus diversity during ART exposure across pediatric patients from the same cohort of the 24 children under study ([@evx193-B36]), indicating that plasma virus diversity is sustained during each phase of viral decay despite the large decreases in the replicating population size. Our results obtained by machine learning showed that those variables related with ART (as year of first ART, NNRTI experience, number of ARVs and of previous ART regimen switches) had an effect on HIV-1 evolutionary parameters. Therefore, the effect of these variables on within-host HIV-1 subtype B evolution should be analyzed in more detail in future studies. The NNRTI experience seems to have a direct effect on genetic diversity and frequency of nonsynonymous changes at *pol* coding region. This result reinforces the importance of treatment on HIV-1 evolution, since virus replication continues in patients under ART, even in patients with viral suppression and persistent low-level viraemia ([@evx193-B33]; [@evx193-B57]).

It is known that the evolutionary pathway and HIV evolution at *pol* can also be highly dependent on the viral genetic background, at DRM as well as nonDRM sites ([@evx193-B41]). We observed that the within-host HIV-1B genetic diversity, nonsynonymous and synonymous mutation rates and selection pressures also changed among patients, probably due to the different selection forces at sampling time and different viral genetic background across patients. In the study we observed a similar number of children carrying DRM over time for NRTI and PI. However, we observed an increase of DRM to NNRTI in the last 5 years, maybe due to the reduced ARVs options in children with high virological failure experience and to the approval of two new NNRTI during that period.

Genetic diversity significantly varied over time, increasing when comparing the baseline versus the last collected viral sequences, mainly due to the accumulation of nonsynonymous mutations. This could be favored by clinical changes over time in patients, including decline of CD4/CD8 ratio, incomplete virus suppression, suboptimal therapies and higher experience to ARVs that promote the fixation of DRM ([@evx193-B31]; [@evx193-B10]; [@evx193-B45]). Note that the number of sites under neutral evolution also increased over time, which would be in apparent contradiction with the observed increase in nonsynonymous mutations. However, if accumulation of nonsynonymous mutations occurred only in a few positions (for instance, DRM-related sites), the rest could have evolved towards neutrality. Indeed, we detected that the number of DRMs increased over time, which would be compatible with this explanation.

According to machine-learning algorithms, other clinical, virological, and epidemiological factors, although lesser, could play a relevant role in DRM fixation and HIV-1B evolution. Thus, VL would not have had an impact on the three HIV-1B evolutionary studied parameters (*d*, *d*~N~, and *d*~S~) in infected children. However other clinical factors (%T CD4, T CD8 count, and CD4/CD8 ratio) appear to contribute to HIV-1 evolution in children. Twenty-three of the 24 children failed to normalize the CD4/CD8 ratio in the last clinical report, even despite VL suppression or low viraemia after effective ART in most of them. The CD4/CD8 ratio is a surrogate marker of immune activation and immunosenescence ([@evx193-B52]; [@evx193-B48]). In the present study we observed a significantly decreased CD4/CD8 ratio over time. This could be due to the higher immune activation and immunosenescence caused by the long-time HIV infection present in vertically HIV-1-infected patients, whose immune system has developed in the presence of the virus since birth or pregnancy ([@evx193-B48]). Consequently, all of these interactive clinical factors could modify the HIV-1 replicative environment, affecting the genetic diversity of HIV-1 in children in agreement with previous reports ([@evx193-B9]; [@evx193-B46]).

Despite the robustness of our predictive models, this study presents limitations. Since all 24 children were perinatally infected, we assumed that HIV-1 was transmitted at delivery time to consider the infant age as HIV-1 exposure time. The exact time of HIV infection is difficult to estimate in infants/children acquiring the HIV infection from their HIV-infected mothers. It will depend on when HIV transmission from mother to child occurred: during 9 months pregnancy, at delivery or during breastfeeding (variable duration after birth). Hence, our estimates of time of infection may have a gap of plus minus a year. However, previous studies indicated little variation in HIV-1 *d*, *d~N~*, and *d~S~* during the first years of infection ([@evx193-B9]). Thus, we do not expect that this uncertainty would have big effects in our results. Another potential caveat is the number of patients included in the study. Although this number and that of analyzed sequences were modest in size, *pol* sequences were sufficient in number to perform an intrahost HIV-1 evolution analysis. Moreover, associated clinical/immunological/virological information was available in all analyzed sequences at sampling time and during the clinical follow up of each patient, and this allowed constructing accurate predictive models. Another limitation of our work is that the monitored time span differed between patients. Using sequences collected during the same time interval would be more a consistent strategy. However, this would have limited our analyses to a time span of 2--3 years, and the analyses shown in [figure 1](#evx193-F1){ref-type="fig"} suggested that few evolutionary changes occur on the HIV-1 genome during such short period of time. Thus, we prioritized an approach that allowed monitoring virus evolution for a longer period. Finally, since only partial *pol* coding region was analyzed, it would be interesting to perform the same analyses using complete *pol* sequences to study the molecular HIV evolution on each three HIV-1 *pol* proteins (PR, RT, and integrase).

In summary, this study identifies for the first time using machine learning and using univariate and multivariate methods, several factors affecting HIV-1B *pol* evolution and those affecting DRM fixation in HIV-1B infected pediatric patients, with high values of precision. More studies are required for a better understanding of HIV evolution across patients and viral genes in children and adolescents with HIV infection.
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[^1]: **Associate editor**: Mary O\' Connell

[^2]: Unknown data in 6^a^, 1^b^, 5^c^, and 4^d^ patients; ^§^Thirteen (68%) children were diagnosed before the first year of life, three (15.8%) children were diagnosed between the first and the fourth year of life, and two children were diagnosed between the fourth and the ninth year of life. ART, antiretroviral treatment. HIV-1 sequences, partial *pol* including the complete PR and the first 334 amino acid residues of RT.

[^3]: Unknown data in 8^a^ and 7^b^ patients. ART, antiretroviral treatment; ARV, antiretroviral; IQR, interquartile range; DRMs, drug resistance mutations to NRTI, NNRTI and PI (major) according to IAS2015 ([@evx193-B58]).

[^4]: Patients ordered according to HIV exposure time. *d*, genetic diversity; *d*~N~, frequency of nonsynonymous mutations; *d*~S~, frequency of synonymous mutations; *d*~N~/*d*~S~, selection pressure; SE, standard error.

[^5]: *d*, genetic diversity; *d*~N~, frequency of nonsynonymous mutations; *d*~S~, frequency of synonymous mutations; DRMs, drug resistance mutations; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; ART, Antiretroviral treatment; HBV, Hepatitis B viruses; HCV, hepatitis C virus; ARVs, antiretroviral drugs; Iint, Integrase inhibitor. In each column, the variables are sorted by relative importance.

[^6]: Predictive models: J48, Classification tree; IB1 and IB3, Nearest-neighbor; CFS, Correlation Feature Selection; *d*, genetic diversity; *d*~N~, frequency of nonsynonymous mutations; *d*~S~, frequency of synonymous mutations; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non nucleoside reverse transcriptase inhibitor; DRM, drug resistance mutations.
